Filing Flows › Regenerative Medical Technology Group (RMTG) › Q4 2024
Regenerative Medical Technology Group (RMTG) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 15, 2025
Regenerative Medical Technology Group (RMTG) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), +145% from a year earlier and +53% from the quarter before. Operating margin was 25.2%, net loss $638K (42.2% of revenue).
Regenerative Medical Technology Group, Q4 2024: revenue $1.5M (+145% year over year), operating margin 25.2%, net loss $638K, operating cash flow $379K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | +53% | +145% |
| Operating profit | $381K | — | — |
| Net earnings | −$638K | — | — |
| Operating cash flow | $379K | +39% | — |
| Free cash flow | $329K | +50% | — |
What changed
Revenue was $1.5M in Q4 2024, up 145% year over year and up 53% from the previous quarter. Patient Procedures was the largest line at 35% of revenue.
Gross margin was 64.9%, down 5.7 points from a year earlier. Operating profit was $381K, a 25.2% margin (up 66.8 points year over year). Operating expenses fell 13% while revenue rose 145%. The quarter ended with a net loss of $638K, narrower than the previous quarter's $887K loss. Net interest and other expense of $1.0M was the main reason.
Operating cash flow was $379K. Working capital and other items added $1.0M. Capital expenditures of $50K left free cash flow of $329K.
Questions
What was Regenerative Medical Technology Group's revenue in the fourth quarter 2024?
Regenerative Medical Technology Group (RMTG) reported revenue of $1.5M for the fourth quarter 2024 (Q4 2024), +145% from a year earlier and +53% from the quarter before.
Was Regenerative Medical Technology Group profitable in the fourth quarter 2024?
Operating profit was $381K (25.2% of revenue) and net loss $638K.
Source: Regenerative Medical Technology Group 10-K on SEC EDGAR.